Lowest Price Guaranteed
Slides
237
Last Updated
March 2025
View Count
9891
The global non-muscle invasive bladder cancer market, valued at USD 2.92 billion in 2024, is projected to reach USD 3.47 billion in 2025 and USD 14.01 billion by 2035, representing a CAGR of 15.0% during the forecast period.
 |
To learn more about this report, request a free sample copy
The new market report provides comprehensive details on the key market players, current trends, drivers, market size, challenges, future opportunities and SWOT analysis.
Non-muscle invasive bladder cancer (NMIBC) is a form of early-stage cancer that remains confined to the inner linings of the bladder. Recently, there has been a surge in the cases of non-muscle invasive bladder cancer among the population worldwide. A recent report published in March 2024 by American Cancer Society estimated that around 83,190 new cases of bladder cancer are diagnosed and around 16,840 deaths occurred due to bladder cancer in United States. It is important to highlight here that people above the age of 55 years are at greater risk of having bladder cancer.
Given the growing incidence of non-muscle invasive bladder cancer, the demand for advanced therapeutic treatment and cancer diagnostic solutions has increased. It is important to highlight here that several chemotherapies and immunotherapies has been developed by the industrial players for the treatment of non-muscle invasive bladder cancer. Among these, Bacillus Calmette-Guerin Vaccine therapy and intravesical chemotherapy are the most popular treatment options that are presently used by healthcare practitioners.
However, the development of bladder cancer immunotherapy and drugs such as immune checkpoint inhibitors to target cancerous cells has recently gained traction. It is important to highlight here that in April 2024, ImmunityBio announced that its ANKTIVA® (N-803, nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guerin received approval from the FDA to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with CIS (carcinoma in situ). The approval of ANKTIVA® marked the launch of next-generation immunotherapy beyond checkpoint inhibitors that not only activate patients NK cells and CD8+ killer T cells but also activate the CD4+ T helper cells for targeting cancerous cells.
Driven by the rising approval of non-muscle invasive cancer targeting therapies, several market players are taking strategic initiatives in the field. However, their primary focus will remain on the development of advanced therapeutic drugs and cost effectiveness of new treatment for bladder cancer to make drug accessible to large pool of population. It is worth mentioning here that in October 2024, UroGen Pharma announced that the FDA has accepted its New Drug Application for (UGN-102 (mitomycin®)) for intravesical solution. Furthermore, the FDA has also assigned a PDUFA (Prescription Drug User Fee Act) goal date of June 13, 2025. Upon final approval, UGN-102 will become the first FDA approved medicine to treat low-grade intermediate-risk non-muscle invasive bladder cancer.
Likewise, several drugs are presently under clinical pipeline and evaluation stage, which we believe will receive approval in the upcoming period. Considering the ongoing approval and increasing research in this field, we believe that non-muscle invasive bladder cancer (NMIBC) market will continue to grow at a steady rate during the forecast period.
The research report provides invaluable information on the key players of the market who are presently active across various segments of the industry as mentioned in the table below.
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Current Market Size | $ 3.47 Billion | |
| Market Size 2035 | $ 14.01 Billion | |
| CAGR (Till 2035) | 15.0% | |
| Type of Stage |
|
|
| Type of Treatment Class |
|
|
| Type of Malignant Potential |
|
|
| Route of Administration |
|
|
| End User |
|
|
| Distribution Channel |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of the market report was to estimate the current size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The non-muscle invasive bladder cancer market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of stage (stage 0a, stage 0is, stage I), type of treatment class (chemotherapies, immunotherapies, surgeries, radiation therapies, and intravesical therapies), type of malignant potential (low-grade tumors and high-grade tumors), route of administration (systemic, intravesical and other routes), end-user (hospitals, specialized clinics and other end users), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies), geographical region (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America) and leading players.
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of stage, the global non-muscle invasive bladder cancer market is segmented into Stage 0a, Stage 0is, Stage I. According to our projection, stage 0a accounts for the highest share (over 40%) of the market. This can be attributed to the fact that stage 0a is most prevalent among population and represent early stage of blader cancer that remain confined to the inner layer of cell lines of bladder. Bladder cancer at this stage is preventable and can be treated with immunotherapy. Additionally, the availability of early detection, effective treatment options and long-term management requirements has contributed to the highest share of this segment. It is important to highlight here that this segment will continue to remain dominant driven by the increasing research for the treatment of stage 0a (carcinoma in-situ stage) cancer and is likely to grow at a higher CAGR during the forecast period.
This segment highlights the distribution of global market across different types of treatment classes, such as chemotherapies, immunotherapies, surgeries, radiation therapies, and intravesical therapies. Among these, chemotherapies hold the highest non-muscle invasive bladder cancer market share (over 45%). This can be attributed to the fact that chemotherapies are necessary for the treatment of patients with non-muscle invasive bladder cancer. Moreover, chemotherapies have also been utilized in combination with immunotherapies to treat patients, which is likely to be a key factor for the highest share.
It is important to highlight here that immunotherapies are gaining momentum during the forecast period. This is likely to be the result of widespread adoption of BCG therapy (an immunotherapy) for the treatment of non-muscle invasive bladder cancer specifically in stage 0a and stage0is. Furthermore, the ongoing research and advancements in new immunotherapies agents such as immune checkpoint inhibitors are gaining popularity, which is likely to be the key reason for highest CAGR of this segment. Notably, the BCG therapies have also be administered to the patients in combination with chemotherapies for the effective treatment of patients. Additionally, the key players such as Bristol Myers Squibb, Merck and Roche are focusing on the development of immunotherapies, which is likely to be a key reason for highest growth rate of this segment during the forecast period.
The global non-muscle invasive bladder cancer market is distributed across different type of grade, such as low-grade tumors and high-grade tumors. It is worth mentioning here that low-grade tumors are likely to dominate the market, accounting for the highest share (nearly 70%) of the market. This can be attributed to the increasing prevalence of low-grade tumors and availability of treatment to cure patients. Moreover, low-grade tumors are easier to detect as they have a papillary appearance (growing outward from the bladder lining), making it more visible during diagnosing tests. Driven by the rising prevalence of low-grade tumor, availability of treatment and easy diagnosis, this segment will continue to remain dominant and is poised to register higher CAGR during the forecast period.
This segment highlights the distribution of global market across different types of routes of administration, such as systemic, intravesical and other routes. According to our projection, currently intravesical accounts for the highest non-muscle invasive bladder cancer market share. This can be attributed to the fact that intravesical route of administration is the most preferable route to deliver therapy directly into the urinary bladder using catheter.
However, in the long run, we believe that systemic route of administration is likely to grow at a higher CAGR during the forecast period. This is likely to be the result of growing shift towards chemotherapies and systemic combination of chemotherapies and immunotherapies to treat non-muscle invasive bladder cancers. These type of therapeutics require delivery of drug through veins for the treatment of patients with advanced stages of bladder cancer.
Based on the end user, the global NMIBC market is segmented into hospitals, specialized clinics and other end users. According to our projection, presently hospitals accounts for the highest share of the market. This can be attributed to the fact that hospitals are currently witness wide pool of patients with non-muscle invasive bladder cancer. Moreover, this type of cancer require advanced facilities and experienced healthcare professionals for appropriate treatment. Additionally, the prescribed chemotherapies and immunotherapies has been delivered in the hospitals, which is likely to be a key reason for the highest share. It is important to highlight here that being primary treatment place, hospitals will continue to maintain dominant position in the market and is likely to grow at a higher CAGR during the projected period.
On the basis of distribution channel, the global non-muscle invasive bladder cancer market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Currently, hospital pharmacies accounts for the largest share of the market. This can be attributed to the fact that hospital pharmacies are the primary distributor of drugs and therapies for the treatment of non-muscle invasive bladder cancer. Moreover, the availability of advance infrastructure in hospitals and healthcare practitioners to deliver targeted drugs to the patients has further increased the demand for therapeutic drugs from the hospitals pharmacies. Driven by the ongoing demand, hospital pharmacies will continue to grow at a steady rate and is anticipated to register higher CAGR during the forecast period.
Based on the geographical regions, the global non-muscle invasive bladder cancer market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. According to our recent study, North America is dominating the market, accounting for the highest share (nearly 45%) of the overall revenue. North America is currently witnessing high prevalence of non-muscle invasive bladder cancer which is likely to be a key reason for highest share.
Moreover, the industrial players established in this region are currently engaged in research and development of advanced bladder cancer alternative medicine. For instance, as of January 2024, Pfizer is currently developing sasanlimab (non-muscle invasive bladder cancer drug) in combination with BCG therapy. Presently, the drug is under Phase III clinical trial and upon approval the drug will be available for the treatment of patients with non-muscle invasive bladder cancer. Similarly, industrial players such as AstraZeneca and Merck are accelerating their research for the development of advanced therapeutic drugs, which is likely to be a key reason for highest share of the market.
However, the market for non-muscle invasive bladder cancer in Asia-Pacific is expected to grow at a substantial CAGR during the forecast period. This can be attributed to the increasing prevalence of non-muscle invasive bladder cancer and rising healthcare expenditure to enhance treatment of patients with this cancer.
The “Non-Muscle Invasive Bladder Cancer Market: Industry Trends and Global Forecasts, till 2035” research report features an extensive study of the focus on competitive landscape of strategic initiatives, emerging mega trends, big pharma initiatives, company profiles and key drivers and restraints. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. Key takeaways of the market data analysis are briefly discussed below.
Currently, the global market landscape of non-muscle invasive bladder cancer is witnessing a wide array of well-established pharmaceutical companies and smaller players. These key players of the market are emphasizing on research and development of advanced therapeutic drugs. In order to cure patients with non-muscle invasive bladder cancer, the market players are focusing on technological innovations that aid in early diagnosis of the cancer. For instance, in September 2024, Olympus launched advanced 4K camera head (Ch-s700-08-LB) for the endoscopic urology and gynecology procedures. This camera head shows great compatibility with VISERA ELITE III video systems to detect different forms of bladder cancer.
Similar to technological innovations, the key players of the industry are aiming to accelerate the pipeline of therapeutic drugs, which is likely to be a key reason for the growth of this industry. Overall, the market is expected to remain competitive during the projected period and cater to the attention of industrial players to take strategic initiatives for finding advanced bladder cancer removal options.
Some of the potential NMIBC market growth drivers include the rising prevalence of bladder cancer, which has necessitated the demand for advanced therapeutic treatment. Moreover, the increasing advancements in immunotherapies to target non-muscle invasive bladder cancer such as immune checkpoint inhibitors and targeted therapies to treat early-stage bladder cancer. Additionally, the increasing research on cancer and therapies development by industry players is likely to fuel the market during the forecast period.
The pipeline has several drugs in phase III and phase II clinical trials. In January 2025, Johnson & Johnson has initiated the New Drug Application (NDA) filing for its drug TAR-200, in phase III clinical trials for BCG-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. Another company, UroGen Pharma filed NDA application for UGN-102 in October 2024 in phase III clinical trial for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.
Driven by the ongoing initiatives and accelerated research, we believe the non-muscle invasive bladder cancer market will continue to witness an upward trajectory.
Despite the high investment in research, the market for non-muscle invasive bladder cancer is witnessing several challenges that needs to be addressed. Some of the potential challenges include high treatment cost and side effects associated with the therapies. Currently, the available advanced therapies are highly expensive, which may limit the access of these therapeutic drugs to the patients. For instance, in United States, the average price of the new bladder cancer treatment options may range from USD 19,521 for stage 0a to USD 1,69,533 for metastatic disease. Furthermore, the side effect and lack of standard screening technologies may further hinder the market growth during the forecast period.
Some of the notable trends that are likely to bolster the growth of this industry includes shift towards personalized medicine and rising collaborations between industrial players. It is important to highlight here that the tailored therapeutic drugs are gaining momentum for managing and treating non-muscle invasive bladder cancer which is likely to be a key growth factor of the market. Additionally, the high demand for non-invasive treatments such as targeted therapies and intravesical therapies has further bolstered the market during the forecast period.
It is important to highlight here that several industrial players are entering into partnership initiatives to develop advanced therapeutic drugs for the treatment of non-muscle invasive bladder cancer and meet the ongoing shortage of available drugs. For instance, in June 2024, ImmunityBio and Serum Institute of India enter into the collaboration agreement to address the shortage of Bacillus Calmette-Guerin therapy which is used to trat bladder cancer. This collaboration initiative will focus on using Anktiva® (recently approved drug by the FDA) in combination with bladder cancer immunotherapy BCG for the treatment of bladder cancer. Driven by the ongoing partnerships, we believe the market will remain progressive during the forecast period.
The global non-muscle invasive bladder cancer (NMIBC) market is currently valued at USD 3.47 billion and is poised to reach USD 14.01 billion by 2035. Driven by the increasing prevalence of bladder cancer across the globe and rising initiatives for drug development, the market is expected to grow at a CAGR of 15.0% during the forecast period.
It is important to highlight here that several drugs are currently under clinical trials showing positive outcomes, marking a significant milestone in the industry. For instance, in June 2024, AstraZeneca’s NIAGARA Phase III clinical trial of Imfinzi® (durvalumab) in combination with chemotherapy has shown significant improvement in the primary endpoint of event-free survival in patients with non-muscle invasive bladder cancer. These promising outcomes is likely to raise the interest of industrial players for strategic initiatives to develop more advanced therapeutic drugs, thereby, keeping the market investible for long term.
Examples of key players engaged in this domain (which have also been captured in this report) include Altor BioScience, AstraZeneca, Bristol-Myers Squibb, CELGENE, Cold Genesys, Eli Lilly, Ferring, GlaxoSmithKline, HERANTIS PHARMA, Heat Biologics, Merck , Novartis, Prometic Life Sciences, Pfizer, Roche, Sanofi, Spectrum Pharmaceuticals, TARIS BIOMEDICAL, Telormedix and Viventia Bio. This market report includes an easily searchable excel database of all the companies focusing on the development of targeted therapies for non-muscle invasive bladder cancer treatment.
Several recent developments have taken place in the non-muscle invasive bladder cancer industry. We have outlined some of these recent initiatives below.